Redmond Asset Management, LLC Cel Sci Corp Transaction History

Redmond Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$2.58 - $4.99 $387 - $748	-150 Reduced 1.09%	13,599 $61,000
Q1 2022 May 03, 2022	SELL	$3.93 - $7.7 $935 - $1,832	-238 Reduced 1.7%	13,749 $54,000
Q4 2021 Feb 04, 2022	BUY	$7.1 - $12.82 $1,427 - $2,576	201 Added 1.46%	13,987 $99,000
Q3 2021 Oct 22, 2021	SELL	$7.64 - $12.49 $3,705 - $6,057	-485 Reduced 3.4%	13,786 $152,000
Q1 2021 May 06, 2021	BUY	$12.0 - $27.64 $1,320 - $3,040	110 Added 0.78%	14,271 $217,000
Q4 2020 Feb 11, 2021	BUY	$11.05 - $16.62 $4,143 - $6,232	375 Added 2.72%	14,161 $165,000
Q3 2020 Nov 06, 2020	BUY	$11.69 - $14.54 $2,630 - $3,271	225 Added 1.66%	13,786 $176,000
Q1 2020 May 06, 2020	BUY	$7.54 - $17.05 $102,249 - $231,215	13,561 New	13,561 $156,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Redmond Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmond Asset Management, LLC with notifications on news.